SG11201809551TA - Selection of bacterial strains useful in allergy treatment - Google Patents

Selection of bacterial strains useful in allergy treatment

Info

Publication number
SG11201809551TA
SG11201809551TA SG11201809551TA SG11201809551TA SG11201809551TA SG 11201809551T A SG11201809551T A SG 11201809551TA SG 11201809551T A SG11201809551T A SG 11201809551TA SG 11201809551T A SG11201809551T A SG 11201809551TA SG 11201809551T A SG11201809551T A SG 11201809551TA
Authority
SG
Singapore
Prior art keywords
international
bacterial strains
allergy
rule
treatment
Prior art date
Application number
SG11201809551TA
Inventor
James Versalovic
Bo Möllstam
Bhanu Priya Ganesh
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of SG11201809551TA publication Critical patent/SG11201809551TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/196235 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: A61K 35/747 (2015.01) Published: — with international search report (Art. 21(3)) (21) International Application Number: — with (an) indication(s) in relation to deposited biological PCT/SE2017/050455 material furnished under Rule 13bis separately from the (22) International Filing Date: description (Rules 13bis.4(d)(i) and 48.2(a)(viii)) — 08 May 2017 (08.05.2017) with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1650620-6 09 May 2016 (09.05.2016) SE (71) Applicant: BIOGAIA AB [SE/SE]; Box 3242, SE-103 64 Stockholm (SE). (72) Inventors: VERSALOVIC, James; 534 South 3rd Street, Bellaire, Texas TX 77401 (US). MOLLSTAM, Bo; Ceder- flychtsvagen 12, SE-443 31 Lerum (SE). GANESH, Bhanu Priya; 8450 Cambridge Street, Apt No 1201, Houston, Texas TX 77054 (US). Agent: AROS PATENT AB; Box 1544, SE-751 45 UP- (74) PSALA (SE). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) under Rule 4.17: Declarations ,- 1 — as to applicant's entitlement to apply for and be granted a patent (Rule 4.170) If M ei SO 0\ 1-1 (54) Title: SELECTION OF BACTERIAL STRAINS USEFUL IN ALLERGY TREATMENT IN ,-1 (57) : Bacterial strains useful in prophylaxis, inhibition and/or treatment of an allergy in a mammal are selected by screening 0 bacterial strains for capability of producing diacylglycerol kinase (DagK). A bacterial strain which is capable of producing DagK is N then selected for use in prophylaxis, inhibition and/or treatment of the allergy.
SG11201809551TA 2016-05-09 2017-05-08 Selection of bacterial strains useful in allergy treatment SG11201809551TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1650620 2016-05-09
PCT/SE2017/050455 WO2017196235A1 (en) 2016-05-09 2017-05-08 Selection of bacterial strains useful in allergy treatment

Publications (1)

Publication Number Publication Date
SG11201809551TA true SG11201809551TA (en) 2018-11-29

Family

ID=58873850

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809551TA SG11201809551TA (en) 2016-05-09 2017-05-08 Selection of bacterial strains useful in allergy treatment

Country Status (11)

Country Link
US (2) US11135255B2 (en)
EP (1) EP3454874A1 (en)
JP (1) JP7030716B2 (en)
CN (1) CN109195612A (en)
AU (1) AU2017262408A1 (en)
BR (1) BR112018072511A2 (en)
CA (1) CA3023867A1 (en)
CL (1) CL2018003167A1 (en)
MX (1) MX2018013660A (en)
SG (1) SG11201809551TA (en)
WO (1) WO2017196235A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021136951A (en) * 2020-03-06 2021-09-16 学校法人麻布獣医学園 Composition containing lactic acid bacteria
CN113073066B (en) * 2021-04-16 2022-01-04 段云峰 Lactobacillus reuteri and application, composition, medicine and food thereof
CN114317326B (en) * 2021-12-06 2023-09-12 浙江工商大学 Lactobacillus sake for relieving anaphylactic reaction and preparation method thereof
CN115025130A (en) * 2022-06-02 2022-09-09 广东南芯医疗科技有限公司 Application of lactobacillus reuteri E9 in preparing medicine for treating or preventing allergic diseases
CN116376758A (en) * 2023-03-15 2023-07-04 广东南芯医疗科技有限公司 Lactobacillus jensenii LS06 and application thereof in preparation of medicines for treating or preventing allergic diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK154078C (en) * 1981-02-06 1989-05-22 Ucb Sa METHOD OF ANALOGUE FOR THE PREPARATION OF 2- (2- (4- (DIPHENYL-METHYL) -1-PIPERAZINYL) ETHOXY) -ACETAMIDES OR ACID ADDITION SALTS.
JP4212838B2 (en) * 2002-06-26 2009-01-21 カルピス株式会社 Antiallergic agent
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
KR100507417B1 (en) * 2003-01-27 2005-08-10 (주) 피엘바이오 Lactic acid bacteria which prevent and/or cure allergic diseases and the allergy-treating products containing these lactic acid bacteria
CA2586316A1 (en) * 2004-11-11 2006-05-18 Argenta Discovery Ltd. Pyrimidine compounds as histamine modulators
US8017592B2 (en) * 2006-04-13 2011-09-13 Alcon Research, Ltd. RNAi-mediated inhibition of histamine receptor H1-related conditions
JP2008127365A (en) * 2006-11-24 2008-06-05 Kowa Co Prophylactic and/or therapeutic agent of allergic disease
US20110217290A1 (en) * 2008-08-18 2011-09-08 Manel Jordana Treatment and/or prevention of peanut induced anaphylaxis
JP2011254773A (en) 2010-06-11 2011-12-22 Bio Plan:Kk Lactic acid bacterium strain and allergy inhibitor using the same
WO2012012390A1 (en) * 2010-07-19 2012-01-26 Marvphyt Development Llc Botanical composition and methods of manufacture and use
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
WO2014130759A1 (en) * 2013-02-21 2014-08-28 University Of Rochester Methods of using histamine receptor agonists and antagonists
JP6195268B2 (en) * 2013-07-18 2017-09-13 国立大学法人徳島大学 Rhinitis prevention and treatment equipment
BR112017019660A2 (en) * 2015-03-26 2018-05-15 Biogaia Ab Histamine-producing lactic acid bacterial strain and method of selecting a lactic acid bacterial strain for use

Also Published As

Publication number Publication date
WO2017196235A1 (en) 2017-11-16
US11135255B2 (en) 2021-10-05
CA3023867A1 (en) 2017-11-16
BR112018072511A2 (en) 2019-03-12
CL2018003167A1 (en) 2018-12-21
EP3454874A1 (en) 2019-03-20
CN109195612A (en) 2019-01-11
AU2017262408A1 (en) 2018-11-15
US20220008491A1 (en) 2022-01-13
MX2018013660A (en) 2019-02-28
JP7030716B2 (en) 2022-03-07
JP2019520801A (en) 2019-07-25
US20190142877A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
SG11201809551TA (en) Selection of bacterial strains useful in allergy treatment
SG11201805835WA (en) Modified oncolytic virus
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201903480TA (en) Cell culture device system and methods of use thereof
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201808476SA (en) Recycling of polymer matrix composite
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201805001UA (en) Method of treating influenza a
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201903786UA (en) Farnesyltransferase inhibitors for use in methods of treating cancer
SG11201908091QA (en) Aqueous anti-pd-l1 antibody formulation
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201805092WA (en) Cortistatin analogs and uses thereof
SG11201906383WA (en) A layered medical data computer architecture
SG11201805141QA (en) Compositions and methods for detecting and treating gastric cancer
SG11201908605XA (en) Antifouling article